Use of Family Relationships in Commercial Claims Data to Characterize Clinical Events of Patients with BRCA1/2
Kevin Gorman1, Xuyang Li1,2, Carolyn Applegate3
1Johns Hopkins Whiting School of Engineering, Institute for Computational Medicine, Baltimore, MD.
Abstract:
BRCA1/2 genetic cascade testing has been studied in small-scale survey and controlled settings, but limited large-scale studies have been done because health records don't typically link family members. This study uses commercial claims data that connect family members on the same insurance plan to identify a large cohort of BRCA1/2 proband and cascade testers and characterizes their breast cancer screening and prevention service utilization. We identified 709 proband and 819 cascade testers. Consistent with clinical guidelines to test for a specific BRCA1/2 variant in a family, more cascade testers received known variant tests than proband testers. Also consistent with guidelines, more proband testers received BRCA1/2 testing after a breast cancer diagnosis compared to cascade testers, and more cascade testers had genetic counseling events pre-BRCA1/2 testing compared to proband testers. This technique and large BRCA1/2 genetic cascade testing cohort can open doors for new research.
Related Concept Videos
Pedigree Analysis
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Cancer Survival Analysis
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

